Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

AVDL 01.06.2025

Full Press ReleaseSEC FilingsOur AVDL Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
  • 01.08.2025 - Avadel Pharmaceuticals Business Update Call
  • 01.08.2025 - Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.08.2025 - 8-K Current report
  • 01.08.2025 - EX-99.1 EX-99.1
PDF Version

DUBLIN,Jan. 06, 2025(GLOBE NEWSWIRE) --Avadel Pharmaceuticals plc(Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors inNovember 2021and the terms and conditions of award agreements covering the grants.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc(Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZTM, was approved by theU.S. Food & Drug Administration(FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visitwww.avadel.com.

Investor Contact:Austin MurtaghPrecision AQaustin.murtagh@precisionaq.com(212) 698-8696

Media Contact:Gabriella GreigReal Chemistryggreig@realchemistry.com(203) 249-2688

Primary Logo

Source: Avadel Pharmaceuticals plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com